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Introduction
Erosive lichen planus mucosae (LPM) is a severe skin and mucosal disease which can seriously hamper nutrition if complications of the pharynx and esophagus are involved, eventually leading to deficiency symptoms. Paul et al. [1] reported on a series of 10 patients with biopsy-proven LPM who were treated with apremilast 20 mg twice daily. Three patients (30%) showed an improvement of two grades on the Physician Global Assessment scale, but all participants experienced significant clinical improvement.
Case Report
We are currently treating a 74-year-old woman with extensive LPM. She started developing genital skin changes at the age of 67 years, which were initially diagnosed as lichen sclerosus et atrophicus. Three years later, erosive stomatitis developed, and a mucosal biopsy showed the distinct histologic pattern of lichen planus. She has reported difficulties in swallowing for the last year. Gastroduodenoscopy confirmed erosive esophagitis and a long stenosis starting 20 cm ab ore ( fig. 1 ).
Immunosuppressive treatment with pulsed intravenous methylprednisolone (125 methylprednisolone on 3 consecutive days, repeated 4 weeks later) did not show any beneficial effect, and azathioprine had to be ceased due to raised transaminases. Meanwhile, she developed a candida superinfection. Esophageal dilatations to 14 mm width were repeatedly performed without any lasting effect.
Having noted the publication of Paul et al. [1] , we started treatment with apremilast. Only 4 weeks later, the patient was clinically free of dysphagia, and the erosive stomatitis had gone into complete remission ( fig. 2) . Control esophagoscopy confirmed a marked recovery of the esophageal mucosa with no recurrence of the former stenosis but some remaining enanthema and increased sensitivity to the mechanical stress caused by the endoscope.
Our case supports the observation of Paul et al. [1] that apremilast may represent a valuable immunomodulatory treatment for LPM. To our knowledge, this is the first report of successful application of apremilast in LPM-associated esophagitis, a rare but serious mucosal disease. The future will show whether more physicians can confirm our observation. Ideally, the effectiveness of apremilast in LPM should be studied in a randomized controlled trial.
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